Coherus Oncology, Inc. (CHRS)

NASDAQ: CHRS · USD

$1.16

+0.09 (+8.4%)· Recorded snapshot

Market cap	179.2M
Revenue (ttm)	50.9M
Net income (ttm)	-132.1M
EPS (ttm)	-$1.00
Shares out	154.5M
Volume	1,203,253
Beta	0.99

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 50.9M
Net income (ttm): -132.1M
EPS (ttm): -$1.00
Market cap: 179.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-178.4

P25 -113.8P50 -46.5P75 -0.9

ROIC-324.3

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All CHRS indicators

Market & fundamental data

Available fields

211

Groups with data

Currency

USD

Showing 211 of 211 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001512762
Company name	Coherus Oncology, Inc.
Country	United States
Country code	US
CUSIP number	19249H103
Earnings date	2026-11-09
Earnings time	amc
Employees	144
Employees change	-33
Employees growth	-18.64%
Enterprise value	$128.1M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2010
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2014-11-06
Is primary listing	Yes
Is SPAC	No
ISIN number	US19249H1032
Last 10-K release date	2026-03-09
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$179.2M
Market cap category	Micro-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$1.16
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	CHRS
U.S. state	California
Website	https://www.coherus.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-86.3%
EV/Sales	2.45x
FCF / EV yield	-148.82%
FCF yield	-105.62%
Forward EV/Sales	1.56x
Forward P/S	2.2x
P/B ratio	2.72x
P/S ratio	3.46x
Price / tangible book value	11.11x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBITDA margin	-295.25%
Gross margin	68.96%
Operating margin	-302.33%
Pretax margin	-316.37%
Profit margin	-259.41%
Profit per employee	$-917,583
Profitable years	2
Revenue per employee	$353,722
ROA	-30.52%
ROA (5Y)	-24.85%
ROCE	-133.13%
ROE	-178.39%
ROIC	-324.31%
ROIC (5Y)	-157.67%
SBC / revenue	21.87%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	4
Gross profit growth	74.65%
Gross profit growth (Q)	46.81%
Gross profit growth 3Y	-27.13%
Gross profit growth 5Y	-36.85%
Net income growth years	3
Revenue growth	61%
Revenue growth (Q)	39.53%
Revenue growth (QoQ)	16.22%
Revenue growth 10Y	1.52%
Revenue growth 3Y	-34.58%
Revenue growth 5Y	-33.6%
Revenue growth quarters	4
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$3.6M
EBIT	$-154M
EBITDA	$-150.4M
EPS	$-1.00
FCF per share	$-1.20
Financing cash flow	$61.8M
Free cash flow	$-186M
Free cash flow minus SBC	$-197.2M
Gross profit	$35.1M
Investing cash flow	$-9.8M
Net borrowing	$-121,000
Net cash flow	$-134M
Net income	$-132.1M
Operating cash flow minus SBC	$-197.2M
Operating income	$-154M
Revenue	$50.9M
Stock-based compensation	$11.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-11.68
Book value per share	$0.39
Debt / equity	0.89
Interest coverage	-16.95
Long-term assets	$57.4M
Long-term liabilities	$54.8M
Net cash (debt)	$51.1M
Net cash / market cap	29.03%
Net cash growth	-72.14%
Net debt / equity	-0.84
Piotroski F-Score	3
Property, plant and equipment	$865,000
Shareholders' equity	$60.8M
Tangible book value	$15.8M
Tangible book value per share	$0.10
Total assets	$191.2M
Total cash	$105.3M
Total debt	$54.2M
Total liabilities	$130.3M
WACC	10.52%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.16
Current assets	$133.8M
Current liabilities	$75.5M
Current ratio	1.77
Inventory turnover	3.11
Net working capital	$-45.1M
Quick ratio	1.58
Working capital	$58.3M
Working capital turnover	0.58

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-14.13%
Dividend yield	0%
Shareholder yield	-14.13%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-96.14%
10Y return CAGR	-27.77%
10Y total return	-96.14%
150-day SMA	$1.44
1D price change	8.41%
1M price change	0.89%
1M total return	0.89%
1W price change	14%
1W total return	14%
1Y price change	-28.75%
1Y return CAGR	-28.77%
1Y total return	-28.75%
20-day SMA	$1.05
200-day SMA	$1.54
3M price change	-21.92%
3M total return	-21.92%
3Y price change	-56.82%
3Y return CAGR	-24.41%
3Y total return	-56.82%
50-day SMA	$1.22
50-day SMA vs 200-day SMA	50under200
52-week high	$2.62
52-week high date	2026-01-27
52-week low	$0.94
52-week low date	2026-10-19
5Y price change	-92.91%
5Y return CAGR	-41.1%
5Y total return	-92.91%
6M price change	-38.04%
6M total return	-38.04%
All-time high	$38.10
All-time high date	2015-07-22
All-time low	$0.66
All-time low date	2024-11-05
Average true range (ATR)	$0.07
Average volume	1.3M
Beta (1Y)	1.4
Beta (2Y)	1.28
Beta (5Y)	0.99
Change from 52-week high	-55.66%
Change from 52-week low	23.4%
Change from all-time high	-97.01%
Change from all-time low	72.65%
Change from open	9.43%
Day's gap	-0.93%
Dollar volume	$1.4M
High price	$1.17
Low price	$1.06
Monthly RSI	39.32
Open price	$1.06
Position in 52-week range	95.24%
Premarket change	2.8%
Premarket close	$1.07
Premarket price	$1.10
Premarket volume	56.4K
Previous close	$1.07
Price vs 150-day SMA	-21%
Price vs 20-day SMA	8.16%
Price vs 200-day SMA	-25.88%
Price vs 50-day SMA	-6.25%
Relative volume	0.92
RSI	53.51
Sharpe ratio	-0.08
Sharpe ratio (3Y)	0.05
Sharpe ratio (5Y)	-0.24
Sortino ratio	-0.04
Sortino ratio (3Y)	0.14
Sortino ratio (5Y)	-0.28
Volume	1.2M
Weekly RSI	42
YTD price change	-19.72%
YTD total return	-19.72%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	135.6M
Float percentage	87.77%
Shares change (QoQ)	13.5%
Shares change (YoY)	14.13%
Shares held by insiders	12.21%
Shares held by institutions	42.77%
Shares outstanding	154.5M
Short % of float	17.21%
Short % of shares	15.11%
Short ratio	17.7 days

Deeper analysis on CHRS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CHRS report

Is a complete CHRS research report available?

No complete published report is available for Coherus Oncology, Inc. (CHRS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Coherus Oncology, Inc. (CHRS)

Price

Financial snapshot

Fair-value bridge

Latest news · CHRS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CHRS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CHRS

Frequently asked questions